Matthys P, Mitera T, Heremans H, Van Damme J, Billiau A
Laboratory of Immunobiology, Rega Institute, University of Leuven, Belgium.
Infect Immun. 1995 Apr;63(4):1158-64. doi: 10.1128/iai.63.4.1158-1164.1995.
Administration of staphylococcal enterotoxin B (SEB) to BALB/c mice was found to induce a cytokine release syndrome hallmarked by weight loss and hypoglycemia. A neutralizing monoclonal antibody against gamma interferon (IFN-gamma) given before SEB counteracted weight loss and prevented hypoglycemia. This protective effect of anti-IFN-gamma antibody was associated with decreased IFN-gamma levels in serum; tumor necrosis factor (TNF) and interleukin-6 (IL-6) levels remained unchanged. A monoclonal anti-IL-6 antibody, known for its ability to cause accumulation of biologically active IL-6 in the circulation, did not modify SEB-induced body weight loss or hypoglycemia. Levels of TNF, IFN-gamma, and IL-6 in serum were all more elevated in anti-IL-6-treated mice than in corresponding SEB-challenged control mice. In D-galactosamine-sensitized mice, SEB-induced weight loss but not hypoglycemia was more severe, resulting mostly in death within 24 h. Higher levels of biologically active TNF and IFN-gamma in serum were noted in these mice than in mice receiving SEB only. In D-galactosamine-sensitized mice, anti-IFN-gamma antibody did prevent hypoglycemia but failed to reduce the severity of the syndrome. Again, TNF levels in anti-IFN-gamma-treated mice remained unchanged. Pretreatment with anti-IL-6 antibody temporarily attenuated SEB-induced hypoglycemia in sensitized mice. Thus, at 6 h post-SEB injection, anti-IL-6-treated mice were less hypoglycemic than corresponding controls. However, at 24 h, hypoglycemia was significantly aggravated. Concomitantly, IL-6 levels were dramatically increased. Neither anti-IFN-gamma nor anti-IL-6 antibody treatment modulated mortality levels in D-galactosamine-sensitized mice. The data obtained with anti-IFN-gamma antibody clearly indicate that endogenous IFN-gamma is instrumental in bringing about hypoglycemia and body weight loss in mice exposed to SEB but also that hypoglycemia is not a crucial determinant of mortality in D-galactosamine-sensitized mice. The data obtained with anti-IL-6 antibody indicate that endogenous IL-6 is involved in regulating the levels of TNF and IFN-gamma in serum.
研究发现,给BALB/c小鼠注射葡萄球菌肠毒素B(SEB)会引发一种以体重减轻和低血糖为特征的细胞因子释放综合征。在注射SEB之前给予抗γ干扰素(IFN-γ)的中和单克隆抗体可抵消体重减轻并预防低血糖。抗IFN-γ抗体的这种保护作用与血清中IFN-γ水平降低有关;肿瘤坏死因子(TNF)和白细胞介素-6(IL-6)水平保持不变。一种以能使生物活性IL-6在循环中蓄积而闻名的抗IL-6单克隆抗体,并未改变SEB诱导的体重减轻或低血糖。抗IL-6处理的小鼠血清中TNF、IFN-γ和IL-6的水平均比相应的SEB攻击对照小鼠更高。在D-半乳糖胺致敏的小鼠中,SEB诱导的体重减轻更为严重,但低血糖并不严重,大多数小鼠在24小时内死亡。与仅接受SEB的小鼠相比,这些小鼠血清中生物活性TNF和IFN-γ的水平更高。在D-半乳糖胺致敏的小鼠中,抗IFN-γ抗体确实可预防低血糖,但未能减轻综合征的严重程度。同样,抗IFN-γ处理的小鼠中TNF水平保持不变。用抗IL-6抗体预处理可暂时减轻致敏小鼠中SEB诱导的低血糖。因此,在注射SEB后6小时,抗IL-6处理的小鼠低血糖程度低于相应的对照小鼠。然而,在24小时时,低血糖显著加重。与此同时,IL-6水平急剧升高。抗IFN-γ和抗IL-6抗体处理均未调节D-半乳糖胺致敏小鼠中的死亡率。用抗IFN-γ抗体获得的数据清楚地表明,内源性IFN-γ有助于导致暴露于SEB的小鼠出现低血糖和体重减轻,但低血糖并不是D-半乳糖胺致敏小鼠死亡的关键决定因素。用抗IL-6抗体获得的数据表明,内源性IL-6参与调节血清中TNF和IFN-γ的水平。